We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
OWC Pharmaceuticals Research Corporation (CE) | USOTC:OWCP | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 30, 2020
OWC Pharmaceutical Research Corp.
(Exact Name of Issuer as Specified in Charter)
Delaware | 000-54856 | 98-0573566 | ||
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission
File Number) |
(I.R.S.
Employer
|
||
2 Ben Gurion St., Ramat Gan Israel 5257334 |
4514760 | |||
(Address of Principal Executive Offices)
|
(Zip Code) |
+972-72-260-8004
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of exchange on which registered | ||
Common Stock |
OWCP |
OTCPQB |
Item 8.01. Other Events.
On March 30, 2020, the board of directors (the “Board”) of OWC Pharmaceutical Research Corp. (the “Company”), approved the deregistration of the Company’s common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the suspension of the Company’s reporting obligations under Section 13(a) and 15(d) of the Exchange Act (the “Deregistration”). The Company intends to file a Form 15 with the Securities and Exchange Commission (the “SEC”) on or about March 31, 2020 to effect the Deregistration. Upon the filing of the Form 15, the Company’s obligation to file periodic and current reports with the SEC, including Forms 10-K, 10-Q and 8-K, will be immediately suspended. In addition, effective March 31, 2020, the Company’s common stock will no longer be eligible for quotation on the OTC QB.
On March 31, 2020, the Company issued a press release announcing its intention to effect the Deregistration. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Information and Exhibits.
(d) Exhibits
99.1 | Press Release, dated March 31, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 31, 2020
OWC PHARMACEUTICAL RESEARCH CORP. | ||
By: | /s/ Zvi Riterband | |
Name: | Zvi Riterband | |
Title: | Chief Executive Officer |
1 Year OWC Pharmaceuticals Rese... (CE) Chart |
1 Month OWC Pharmaceuticals Rese... (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions